EC Number   |
Application |
Reference |
|---|
   3.2.1.35 | analysis |
cancer cell lines often secrete hyaluronidase, the enzyme might therefore be a marker for growing tumours |
650509 |
| 3.2.1.35 | biotechnology |
a fluorescent substrate (FRET-HA) to quantitatively assess hyaluronidase activity is developed |
695542 |
| 3.2.1.35 | biotechnology |
novel products in hyaluronan digested by commercially available bovine testicular hyaluronidase are found which originate from a novel enzyme contaminat in the BTH |
698133 |
| 3.2.1.35 | diagnostics |
increased concentration of HYAL1-type enzyme correlates with tumour progression and is a marker for grade (G) 2 or 3 bladder cancer |
652294 |
| 3.2.1.35 | medicine |
as major hyaluronidases in human cells, HYAL1 and HYAL2 may control intercellular interactions and microenvironment of tumour cells providing excellent targets for cancer treatment |
694822 |
| 3.2.1.35 | medicine |
bovine hyaluronidase is an adjuvant for infiltration anesthesia. By degrading hyaluronan in the extracellular matrix, hyaluronidase increases membrane permeability, thereby rendering tissues more permeable to injected fluids. As a consequence, hyaluronidase reduces viscosity of hyaluronan which improves tissue diffusion and the resorption rate of excess fluids. Co-administration of hyaluronidase is a potential option to enhance the effectiveness of local anesthesia, increasing the analgesic efficacy with respect to the anesthetized area per time (e.g., subcutaneous and intramuscular injections). Hyaluronidase is used in ophthalmic surgery in combination with local anesthetics for peritubular, retrotubular or sub-Tenon's anesthesia and is established in other surgical disciplines, including dermatosurgery. Injection of hyaluronidase-based fillers in aesthetic dermatology |
750477, 753495 |
| 3.2.1.35 | medicine |
enzyme is the target for immunotherapy of allergen reaction |
653937 |
| 3.2.1.35 | medicine |
human cancers grown in SCID mice regress dramatically following administration of purified testicular hyaluronidase. Hyaluronidase treatment also prevents lymph node invasion in a murine model for T-cell lymphoma |
701231 |
| 3.2.1.35 | medicine |
hyaluronidase 1 is a prognostic indicator for both local recurrence and progression of non-muscle-invasive bladder cancer after transurethral resection |
703581 |
| 3.2.1.35 | medicine |
hyaluronidase correlates with tumor progression which is documented in tumors of the male genito-urinary tract, in prostate and urinary bladder cancers. Aggressiveness of other human cancers also correlates with hyaluronidase, including breast and laryngeal cancer |
701231 |
